Lineage Cell Reports Fourth Quarter and Full Year 2023 Financial Results
Lineage Cell to Report Fourth Quarter and Full Year 2023 Financial Results
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant
Lineage Announces Submission of OPC1 New Drug Amendment for Spinal Cord Injury
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at Baird’s 2023 Global Healthcare Conference, in a fireside chat hosted by Jack K. Allen, CFA, Senior Research Analyst, Robert W. Baird & Co. Incorporated, on September 12th, 2023 at 12:50pm ET. Baird’s 2023 Global Healthcare Conference is being held at the InterContinental New York Barclay Hotel. In addition, Mr. Culley will also be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, on September 13th, 2023 at 10:30am ET. The H.C. Wainwright 25th Annual Global Investment Conference is being held at the Lotte New York Palace Hotel.